Insulet (PODD) Q4 Earnings and Revenues Top Estimates

Core Insights - Insulet (PODD) reported quarterly earnings of $1.15 per share, exceeding the Zacks Consensus Estimate of$1.05 per share, but down from $1.40 per share a year ago, representing an earnings surprise of 9.52$597.5 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.73% and up from 509.8 million year-over-year [2] - Insulet has outperformed the S&P 500, gaining approximately 8.7% since the beginning of the year compared to the S&P 500's 4.5% increase [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is 0.79 on revenues of $538.9 million, and for the current fiscal year, it is$3.92 on revenues of $2.42 billion [7] - The estimate revisions trend for Insulet is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Products industry, to which Insulet belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]